The acquisition aims to expand Kite Pharma’s capabilities in in vivo CAR T-cell therapy research and development.

The company is testing its lead asset, a CAR T/NK-cell therapy, in a Phase I trial in patients with B-cell malignancies.

Gilead shares slip after CVS refused to add its new HIV drug, Yeztugo, while its Kite unit struck a $350 million deal with ...

所以对于各IN VIVO CAR-T平台/公司的评估，评估其载体特点及后续的转染、表达、安全性等参数是重中之重。目前主流的载体分为病毒载体和非病毒载体，后续我将根据载体及代表公司，做个系列的文章来梳理。今天重点来讨论一下病毒载体，特别是慢病毒载体。

Biotech investors tend to focus on small-cap companies in search of the next big breakthrough. Still, one established player ...